Brief: Polaryx Therapeutics Receives FDA Fast Track Designation For Plx‑200 For Late‑Infantile Neuronal Ceroid Lipofuscinosis (Cln2 Disease)
17/03/2026 12:42
March 17 (Reuters) - Polaryx Therapeutics, Inc PLYX.O: POLARYX THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR PLX‑200 FOR LATE‑INFANTILE NEURONAL CEROID LIPOFUSCINOSIS (CLN2 DISEASE) POLARYX THERAPEUTICS, INC - TO INITIATE SOTERIA TRIAL IN Q3 2026 FOLLOWING FDA SAFE TO PROCEED LETTER Source text: ID:nGNX13FLR Further company coverage: PLYX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polaryx Therapeutics
See all newsBrief: Polaryx Therapeutics Closes $10 Million Private Placement Equity Financing
U.S. STOCKS ON THE MOVE-Northern Trust, UnitedHealth, Tractor Supply
U.S. STOCKS ON THE MOVE-Intel, Teradyne, MSCI
Polaryx rises after FDA grants fast-track status for rare disease drug
Brief: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations For All Four Indications To Be Evaluated In The Soteria Basket Trial